To include your compound in the COVID-19 Resource Center, submit it here.

Standing pat

Why generalists have yet to return to biotech

Investors agree that new generalist money will be needed to sustain biotech’s rally in 2H17, but the opposite has played out in the early innings.

Mixed results from key 3Q17 milestones and the continued lack of big acquisition deals have kept generalists looking elsewhere -- and this isn’t expected

Read the full 482 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE